Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
In vitro analysis of anti-drug and autoantibody production in inflammatory rheumatic disease patients on biologic therapy
NL-OMON42179Recruiting
- Sponsor
- Jan van Breemen Institute
- Start
- Jun 2015
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of adalimumab, etanercept, golimumab, certolizumab pegol and abatacept in rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) (5 arms), sponsored by Jan van Breemen Institute. Primary endpoints: Plasma antibody and inflammatory characteristics, PBMC cellular characteristics and 1 more. Started Jun 2015; status: recruiting.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)ankylosing spondylitis (AS)psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NL-OMON42179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42179.